City
Epaper

S Korea targets homegrown Covid-19 vax early next year

By IANS | Updated: February 22, 2021 19:45 IST

Seoul, Feb 22 South Korea could produce locally developed vaccines against the novel coronavirus early next year, the ...

Open in App

Seoul, Feb 22 South Korea could produce locally developed vaccines against the novel coronavirus early next year, the ICT minister said on Monday, as the country seeks to prepare for a drawn-out fight against the pandemic.

Minister of Science and ICT Choi Ki-young said the government will continue to support development of local vaccines against the virus even though the country has secured enough vaccines from foreign pharmaceutical companies, such as Pfizer, Moderna and AstraZeneca.

The country plans to roll out its COVID-19 inoculation program with AstraZeneca's vaccines Friday, while inoculation with Pfizer's vaccines will start Saturday. South Korea has secured enough coronavirus vaccines to inoculate 79 million people, higher than its population of 51.6 million.

"We don't know how long the vaccines will stay effective, and there could be many strains of the virus," Choi said in a briefing. "We can't simply rely on foreign vaccines."

"If we continue to support development of local vaccines, we will be able to respond faster to new diseases or virus strains."

Last week, the government said it would inject 131.4 billion won (US$118.4 million) this year to help local pharmaceutical companies conduct clinical trials on COVID-19 vaccines and treatment.

The minister said local pharmaceutical companies are currently developing synthetic antigen vaccines, DNA vaccines and a viral vector vaccine against the virus and that phase 3 clinical trials of a homegrown vaccine could take place at the end of this year if development goes as planned.

Choi, however, warned that there are numerous uncertainties as problems could arise in clinical trials.

He said it would be difficult to conduct phase 3 trials in South Korea as it would require a lot of COVID-19 patients and there could be cost-related challenges.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: seoulICTSouth KoreaRepublic of koreaPfizerPfizer inc.Delle poole
Open in App

Related Stories

EntertainmentBTS RM Shares Rare Glimpse of His Family, ARMY Praises Rapper’s Bond and Openness

EntertainmentBTS Comeback Update: Jimin Says Group Has Finished Recording New Album (Watch Video)

Entertainment‘The Glory’ Actor Jung Sung-il Announces Divorce With Wife After Nine-Year Marriage

EntertainmentBTS RM Shares His Views on Getting Married and Having Kids in Recent Live Session (Watch Video)

EntertainmentBTS Jungkook Looks Like K-Drama Lead at New York Fashion Week, Fans Call Him Prince Charming

Health Realted Stories

HealthFour more people die of dengue in Bangladesh, 2025 death toll crosses 340

HealthBrain fever: Karnataka govt releases guidelines for Sabarimala pilgrims

HealthPrevalence of multidrug-resistant organisms highest in Indian patients: Study

HealthIndian space sector to grow from $8 billion to $45 billion in next decade: Jitendra Singh 

HealthLeveraging AI can transform India’s healthcare landscape: Report